# Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

> **NCT03615066** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 67 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Placebo
- **DRUG:** Selgantolimod
- **DRUG:** TAF

## Key facts

- **NCT ID:** NCT03615066
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-28
- **Primary completion:** 2019-12-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03615066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03615066, "Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03615066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*